Epidemiology of Heart Failure with Preserved Ejection Fraction

Abhinav Dhingra, Aayushi Garg, Simrat Kaur, Saurav Chopra, Jaspreet Singh Batra, Ambarish Pandey, Antoine H. Chaanine, Sunil K. Agarwal

Research output: Contribution to journalReview article

49 Citations (Scopus)

Abstract

The prevalence of heart failure (HF) and its subtype, HF with preserved ejection fraction (HFpEF), is on the rise due to aging of the population. HFpEF is convergence of several pathophysiological processes, which are not yet clearly identified. HFpEF is usually seen in association with systemic diseases, such as diabetes, hypertension, atrial fibrillation, sleep apnea, renal and pulmonary disease. The proportion of HF patients with HFpEF varies by patient demographics, study settings (cohort vs. clinical trial, outpatient clinics vs. hospitalised patients) and cut points used to define preserved function. There is an expanding body of literature about prevalence and prognostic significance of both cardiovascular and non-cardiovascular comorbidities in HFpEF patients. Current therapeutic approaches are targeted towards alleviating the symptoms, treating the associated comorbid conditions, and reducing recurrent hospital admissions. There is lack of evidence-based therapies that show a reduction in the mortality amongst HFpEF patients; however, an improvement in exercise tolerance and quality of life is seen with few interventions. In this review, we highlight the epidemiology and current treatment options for HFpEF.

Original languageEnglish (US)
Pages (from-to)354-365
Number of pages12
JournalCurrent Heart Failure Reports
Volume11
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Epidemiology
Heart Failure
Exercise Tolerance
Sleep Apnea Syndromes
Ambulatory Care Facilities
Atrial Fibrillation
Lung Diseases
Comorbidity
Cohort Studies
Therapeutics
Quality of Life
Demography
Clinical Trials
Hypertension
Kidney
Mortality
Population

Keywords

  • Diastolic heart failure
  • Epidemiology
  • Preserved ejection fraction
  • Prevalence

ASJC Scopus subject areas

  • Emergency Medicine
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Dhingra, A., Garg, A., Kaur, S., Chopra, S., Batra, J. S., Pandey, A., ... Agarwal, S. K. (2014). Epidemiology of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports, 11(4), 354-365. https://doi.org/10.1007/s11897-014-0223-7

Epidemiology of Heart Failure with Preserved Ejection Fraction. / Dhingra, Abhinav; Garg, Aayushi; Kaur, Simrat; Chopra, Saurav; Batra, Jaspreet Singh; Pandey, Ambarish; Chaanine, Antoine H.; Agarwal, Sunil K.

In: Current Heart Failure Reports, Vol. 11, No. 4, 01.01.2014, p. 354-365.

Research output: Contribution to journalReview article

Dhingra, A, Garg, A, Kaur, S, Chopra, S, Batra, JS, Pandey, A, Chaanine, AH & Agarwal, SK 2014, 'Epidemiology of Heart Failure with Preserved Ejection Fraction', Current Heart Failure Reports, vol. 11, no. 4, pp. 354-365. https://doi.org/10.1007/s11897-014-0223-7
Dhingra, Abhinav ; Garg, Aayushi ; Kaur, Simrat ; Chopra, Saurav ; Batra, Jaspreet Singh ; Pandey, Ambarish ; Chaanine, Antoine H. ; Agarwal, Sunil K. / Epidemiology of Heart Failure with Preserved Ejection Fraction. In: Current Heart Failure Reports. 2014 ; Vol. 11, No. 4. pp. 354-365.
@article{840b95fdaab344a0a2b7d702df5ac4c6,
title = "Epidemiology of Heart Failure with Preserved Ejection Fraction",
abstract = "The prevalence of heart failure (HF) and its subtype, HF with preserved ejection fraction (HFpEF), is on the rise due to aging of the population. HFpEF is convergence of several pathophysiological processes, which are not yet clearly identified. HFpEF is usually seen in association with systemic diseases, such as diabetes, hypertension, atrial fibrillation, sleep apnea, renal and pulmonary disease. The proportion of HF patients with HFpEF varies by patient demographics, study settings (cohort vs. clinical trial, outpatient clinics vs. hospitalised patients) and cut points used to define preserved function. There is an expanding body of literature about prevalence and prognostic significance of both cardiovascular and non-cardiovascular comorbidities in HFpEF patients. Current therapeutic approaches are targeted towards alleviating the symptoms, treating the associated comorbid conditions, and reducing recurrent hospital admissions. There is lack of evidence-based therapies that show a reduction in the mortality amongst HFpEF patients; however, an improvement in exercise tolerance and quality of life is seen with few interventions. In this review, we highlight the epidemiology and current treatment options for HFpEF.",
keywords = "Diastolic heart failure, Epidemiology, Preserved ejection fraction, Prevalence",
author = "Abhinav Dhingra and Aayushi Garg and Simrat Kaur and Saurav Chopra and Batra, {Jaspreet Singh} and Ambarish Pandey and Chaanine, {Antoine H.} and Agarwal, {Sunil K.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11897-014-0223-7",
language = "English (US)",
volume = "11",
pages = "354--365",
journal = "Current Heart Failure Reports",
issn = "1546-9530",
number = "4",

}

TY - JOUR

T1 - Epidemiology of Heart Failure with Preserved Ejection Fraction

AU - Dhingra, Abhinav

AU - Garg, Aayushi

AU - Kaur, Simrat

AU - Chopra, Saurav

AU - Batra, Jaspreet Singh

AU - Pandey, Ambarish

AU - Chaanine, Antoine H.

AU - Agarwal, Sunil K.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The prevalence of heart failure (HF) and its subtype, HF with preserved ejection fraction (HFpEF), is on the rise due to aging of the population. HFpEF is convergence of several pathophysiological processes, which are not yet clearly identified. HFpEF is usually seen in association with systemic diseases, such as diabetes, hypertension, atrial fibrillation, sleep apnea, renal and pulmonary disease. The proportion of HF patients with HFpEF varies by patient demographics, study settings (cohort vs. clinical trial, outpatient clinics vs. hospitalised patients) and cut points used to define preserved function. There is an expanding body of literature about prevalence and prognostic significance of both cardiovascular and non-cardiovascular comorbidities in HFpEF patients. Current therapeutic approaches are targeted towards alleviating the symptoms, treating the associated comorbid conditions, and reducing recurrent hospital admissions. There is lack of evidence-based therapies that show a reduction in the mortality amongst HFpEF patients; however, an improvement in exercise tolerance and quality of life is seen with few interventions. In this review, we highlight the epidemiology and current treatment options for HFpEF.

AB - The prevalence of heart failure (HF) and its subtype, HF with preserved ejection fraction (HFpEF), is on the rise due to aging of the population. HFpEF is convergence of several pathophysiological processes, which are not yet clearly identified. HFpEF is usually seen in association with systemic diseases, such as diabetes, hypertension, atrial fibrillation, sleep apnea, renal and pulmonary disease. The proportion of HF patients with HFpEF varies by patient demographics, study settings (cohort vs. clinical trial, outpatient clinics vs. hospitalised patients) and cut points used to define preserved function. There is an expanding body of literature about prevalence and prognostic significance of both cardiovascular and non-cardiovascular comorbidities in HFpEF patients. Current therapeutic approaches are targeted towards alleviating the symptoms, treating the associated comorbid conditions, and reducing recurrent hospital admissions. There is lack of evidence-based therapies that show a reduction in the mortality amongst HFpEF patients; however, an improvement in exercise tolerance and quality of life is seen with few interventions. In this review, we highlight the epidemiology and current treatment options for HFpEF.

KW - Diastolic heart failure

KW - Epidemiology

KW - Preserved ejection fraction

KW - Prevalence

UR - http://www.scopus.com/inward/record.url?scp=84920834648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920834648&partnerID=8YFLogxK

U2 - 10.1007/s11897-014-0223-7

DO - 10.1007/s11897-014-0223-7

M3 - Review article

C2 - 25224319

AN - SCOPUS:84920834648

VL - 11

SP - 354

EP - 365

JO - Current Heart Failure Reports

JF - Current Heart Failure Reports

SN - 1546-9530

IS - 4

ER -